Releases Details
Issue of Equity and Total Voting Rights
("
Issue of Equity
Increase to
Block Listing Return
and
Total Voting Rights
Application has also been made for admission to trading on AIM in respect of an additional block listing of 13 million Common Stock to become effective on
AIM Block Admission Return
a.
b.
MaxCyte Long Term Incentive Plan
c. Period of return:
From:
d. Number and class of securities not issued under scheme
1,000,000 ordinary shares of common stock of
e. Number of shares issued under scheme during period
921,342 ordinary shares of common stock of
f. Balance under the scheme not yet issued at the end of the period.
78,658 ordinary shares of common stock of
g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional block listing application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.
1,000,000 common stock of
942,900 common stock of
Please confirm your total issued share capital as at the end of this period.
(If you hold any shares in Treasury state the figure separately);
As at
Treasury shares (if applicable) ………Nil………….
h. Contact name and telephone number for queries;
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer
+1 301 944 1660
Date
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
MaxCyte Contacts:
Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer
|
+1 301-944-1660 |
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
Joint Corporate Broker James Black / Duncan Monteith / Matthew O'Dowd
|
+44 (0)20 7260 1000 |
Joint Corporate Broker Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams
|
+44 (0) 20 7710 7600
|
UK IR Adviser Mary-Jane Elliott Chris Welsh
|
+44 (0)203 709 5700
|
US IR Adviser David Deuchler, CFA |
+1 415-937-5400
|
US Media Relations Jamie Lacey-Moreira |
+1 410 299-3310
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the